What question did this study set out to answer?

This research aims to create a living bacterial platform for targeted tumor interventions using protein degradation and immunotherapy.

EngineeringNonpathogenic Bacteria for SynergisticTumor-Targeted Protein Degradation and Immunotherapy by Checkpoint-InhibitingNanobodies

View Full Paper

Ask AI

Bookmark

Randomized trial demonstrates tumor-targeted protein degradation in engineered bacteria, indicating enhanced immunotherapy potential.

This research aims to create a living bacterial platform for targeted tumor interventions using protein degradation and immunotherapy.
Developed nonpathogenic E. coli K12 for protein degradation and nanobody secretion.
Utilized metabolic labeling and bioorthogonal click chemistry for surface display of transferrin-CD24 antibody chimeras.
Evaluated the therapeutic effect in breast and liver cancer models.
Engineered bacteria achieved significant tumor growth inhibition (P<0.001) in both cancer models.
Enhanced macrophage-mediated phagocytosis and CD8+ T cell immunity were observed.
Prolonged animal survival correlated with modifications in the tumor microenvironment.

A 2026 study studied this question.

View Full Paper

Ask AI

Bookmark